Latest News & Features
Americas
The US government has asked pharmaceutical company Mylan to testify with information on the price of a generic antibiotic product it makes. 7 December 2015
Americas
Valeant Pharmaceuticals has slammed Allergan’s attempt to market a generic version of its Relistor (methylnaltrexone bromide) drug. 4 December 2015
Americas
There were no surprises, but plenty of alarms yesterday following the US Court of Appeals for the Federal Circuit’s decision to reject Sequenom’s request for a re-hearing of its dispute with Ariosa Diagnostics en banc. 3 December 2015
Americas
The US Court of Appeals for the Federal Circuit has rejected Sequenom’s petition to re-hear its dispute with Ariosa Diagnostics en banc. 2 December 2015
Big Pharma
Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time. 2 December 2015
Medtech
The US Supreme Court has rejected both Nautilus’s and Covidien’s attempt to reverse patent infringement judgments in two separate disputes centring on medical devices. 1 December 2015
Americas
A group of technology companies has urged the US Supreme Court to re-hear the Nautilus v Biosig case, arguing that the US Court of Appeals for the Federal Circuit failed to apply the “reasonable certainty” standard for determining whether a patent claim is indefinite. 30 November 2015
Asia-Pacific
Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company. 27 November 2015
Big Pharma
The English High Court has rejected Pfizer’s attempt to amend a patent that was ruled partially invalid in its long-standing dispute with generics companies Mylan and Allergan. 26 November 2015
Americas
Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board review the validity of a patent owned by Alpex Pharma. 25 November 2015